An unfavourable environment weighs on KAMADA (TAE), which sees a downgrade to Slightly Negative
The independent financial analyst theScreener just requalified the general evaluation of KAMADA (TAE) (IL), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date January 14, 2022, the closing price was ILS 20.97 and its target price was estimated at ILS 17.05.Kamada is a plasma derived protein therapeutics company. Co. develops and produces specialty plasma-derived protein therapeutics and markets these products through strategic partners in the United States and Europe and directly, through local distributors, in several emerging markets. Co.'s flagship product is "Glassia". Co.'s activities are divided into two operating segments: Proprietary Products, which develops, manufactures and sales plasma-derived therapeutics products; and Distribution which distributes drugs in Israel manufactured by other companies for clinical uses, most of which are produced from plasma or its derivatives products.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.